| Viking Thera (VKTX) | |||
|---|---|---|---|
| 76.97 1.21 (1.6%) | 05-03 16:00 | ||
| Open: | 74.7 | Pre. Close: | 75.76 |
| High: | 77.68 | Low: | 72.88 |
| Volume: | 3,699,472 | Market Cap: | 8,487(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 95.78  One year: 111.87 |
| Support: | Support1: 69.42 Support2: 61.64 |
| Resistance: | Resistance1: 82.00 Resistance2: 95.78 |
| Pivot: | 70.04  |
| Moving Averages: | MA(5): 76.83 MA(20): 70.52 MA(100): 47.73 MA(250): 28.25 |
| MACD: | MACD(12,26): 1.97 Signal(12,26,9): 1.12 |
| %K %D: | %K(14,3): 78.70 %D(3): 83.91 |
| RSI: | RSI(14): 59.51 |
| 52-Week: | High: 99.41 Low: 8.28 Change(%): 236.7 |
| Average Vol(K): | 3-Month: 6636 10-Days: 2941 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 77.719 - 78.102 | 78.102 - 78.49 |
| Low: | 72.015 - 72.396 | 72.396 - 72.783 |
| Close: | 76.331 - 76.961 | 76.961 - 77.599 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VKTX ] has closed below upper band by 18.4%. Bollinger Bands are 10.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. |
| Stock chart |
|---|
 |
| Stock News |
|---|
|
Tue, 30 Apr 2024 5 'Strong Buy' Growth Stocks to Grab This May - The Globe and Mail Sun, 28 Apr 2024 Is Viking Therapeutics Incredibly Undervalued? - The Globe and Mail Tue, 26 Mar 2024 Viking Therapeutics stock gains on data for weight loss drug - Seeking Alpha Wed, 20 Mar 2024 Viking Therapeutics’ Meteoric Rise Shifts Spotlight to Biotech Sector - The Healthcare Technology Report. Mon, 11 Mar 2024 Is Viking Therapeutics Stock a Buy? - Yahoo Finance Thu, 07 Mar 2024 Why Viking Therapeutics Stock Is Plunging Today - Yahoo Finance |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Capital Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 110.22 |
| Shares Float (M) | 95.04 |
| % Held by Insiders | 6.03 |
| % Held by Institutions | 71.48 |
| Shares Short (K) | 9520 |
| Shares Short Prior Month (K) | 12280 |
| Stock Financials | |
|---|---|
| EPS | -0.910 |
| Book Value (p.s.) | 3.480 |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | -23.5 |
| Return on Equity (ttm) | -34.8 |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -73.38 |
| Levered Free Cash Flow (M) | -42.36 |
| Stock Valuation | |
|---|---|
| PE Ratio | -84.58 |
| PEG Ratio | -1.44 |
| Price to Book value | 22.12 |
| Price to Sales | |
| Price to Cash Flow | -115.61 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
